Bristol-Myers' Unrestricted Grants Fund Neuroscientists' 'Wildest Ideas'

Why would a major pharmaceutical company like Bristol-Myers give half a million dollars to a neuroscientist without requiring him to submit a grant application? And why would the grant be unrestricted, with no spending guidelines? Why wouldn’t the principal investigator be required to offer the company first right of refusal to any patent resulting from the research—or even to write up periodic reports? “It’s seed money for good science,” says Davis L. Temple, Jr

| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

Why would a major pharmaceutical company like Bristol-Myers give half a million dollars to a neuroscientist without requiring him to submit a grant application? And why would the grant be unrestricted, with no spending guidelines? Why wouldn’t the principal investigator be required to offer the company first right of refusal to any patent resulting from the research—or even to write up periodic reports?

“It’s seed money for good science,” says Davis L. Temple, Jr., vice president in charge of central nervous system research at Bristol-Myers’ Pharmaceutical Research and Development Division in New York. Temple chairs the committee that selects the recipients of Bristol-Myers’ Unrestricted Neuroscience Grants. The program, he says, “enables people in industry to become better acquainted with some of the academic scientists.” Bristol-Myers’ goal, Temple explains, is to fund “basic science that might provide key findings” leading to a cure for the central nervous system diseases “that are ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Barbara Spector

    This person does not yet have a bio.

Published In

Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide